We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MHRA Outlines Submissions Process in Case of No-Deal Brexit
MHRA Outlines Submissions Process in Case of No-Deal Brexit
In new guidance issued Monday, the UK’s Medicines and Health products Agency (MHRA) outlined how drugmakers and clinical trial sponsors can access the new MHRA gateway for UK submissions in case of a no-deal Brexit.